好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

7T MRI Study of Cortical and Thalamic Atrophy in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease and Multiple Sclerosis
Multiple Sclerosis
S3 - Multiple Sclerosis: Clinical Trials (2:48 PM-3:00 PM)
010
Cortical and thalamic damage are established pathological features of multiple sclerosis (MS). In myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) deep grey matter and cortical lesions are commonly found, particularly during an acute attack. It is not yet known if such lesions later result in volume loss in these regions in MOGAD.

To investigate the presence and topography of grey matter atrophy in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS).

We enrolled 23 patients with MOGAD, 17 patients with MS, and 18 healthy volunteers. Each subject underwent a 7T brain MRI scan including high-resolution 3D acquired sequences: T1-weighted MP2RAGE (0.75 mm isotropic), T2-weighted SPACE (0.75 mm isotropic) and double inversion recovery (DIR)-SPACE (1 mm isotropic). T2-hyperintense lesions were segmented on DIR images, and FreeSurfer software (v7.3.2) was used to obtain deep gray matter volumes, in particular thalamus, as well as cortical volumes/thickness. Age- and sex-adjusted MANCOVA on ranked variables was used for between groups comparisons.

T2-hyperintense lesion count and volumes were higher in MS than MOGAD (p<0.001). Compared to healthy volunteers, participants with both MOGAD and MS displayed a global grey matter atrophy, involving the cortex, the thalami, and the other grey matter nuclei (p<0.001). White matter atrophy was only observed among MS patients (p=0.009). No significant volumetric differences emerged in the comparison between MOGAD and MS patients.

Despite small sample size, this study shows evidence of grey matter atrophy in MOGAD in both the thalamus and cerebral cortex, despite a lower lesion burden compared to MS. Since the majority of lesions are known to resolve in MOGAD, further research is needed to understand whether grey matter atrophy is associated with prior demyelinating attacks.

Authors/Disclosures
Laura Cacciaguerra, MD, PhD (Mayo Clinic)
PRESENTER
Dr. Cacciaguerra has nothing to disclose.
Andrew Fagan, PhD Prof. Fagan has nothing to disclose.
John Port, MD, PhD The institution of Prof. Port has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clario.
Pearse Morris, kjsdfkshd Ms. Morris has nothing to disclose.
John Chen John Chen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. John Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen.
W. O. Tobin, PhD, MBBCh, BAO, FAAN (Mayo Clinic) The institution of Dr. Tobin has received research support from Mallinckrodt. Dr. Tobin has received publishing royalties from a publication relating to health care. Dr. Tobin has received personal compensation in the range of $500-$4,999 for serving as a Speaker with NeurologyLive.
Eoin P. Flanagan, MBBCh, FAAN (Mayo Clinic) The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.
Jan-Mendelt Tillema, MD (Mayo Clinic) Dr. Tillema has nothing to disclose.